The clinical developement of ATL1103 is progressing aggressivly through the current clinical human trials and i would expect from this base we should see ATL1103 focused on commercial production to market.This would sent the value of ANP stock soaring,
As you mentioned ANP have previously reported that ATL1103 injection suppressed circulating levels of IGF-I in primates and that toxicology studies have been completed with complete success hence the human trials now at Austin Hospital.
Robbbssstttarrrr
- Forums
- ASX - By Stock
- PER
- should buy now
should buy now, page-12
-
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.9¢ |
Change
-0.002(2.47%) |
Mkt cap ! $81.90M |
Open | High | Low | Value | Volume |
8.0¢ | 8.1¢ | 7.8¢ | $1.034M | 12.98M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 349999 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 305419 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 349999 | 0.079 |
13 | 925066 | 0.078 |
11 | 938445 | 0.077 |
6 | 776200 | 0.076 |
12 | 1232581 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 305419 | 1 |
0.081 | 550144 | 3 |
0.082 | 599880 | 3 |
0.084 | 400000 | 1 |
0.085 | 40000 | 1 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |